Fulgent Genetics Inc
NASDAQ:FLGT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.71
30.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fulgent Genetics Inc
Net Margin
Fulgent Genetics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | US |
| Market Cap | 545.7m USD |
| Net Margin |
-59%
|
| Country | US |
| Market Cap | 91.8B USD |
| Net Margin |
1%
|
| Country | US |
| Market Cap | 87.7B EUR |
| Net Margin |
1%
|
| Country | US |
| Market Cap | 73B USD |
| Net Margin |
1%
|
| Country | DE |
| Market Cap | 24.9B EUR |
| Net Margin |
3%
|
| Country | US |
| Market Cap | 20.1B USD |
| Net Margin |
3%
|
| Country | DE |
| Market Cap | 18.8B EUR |
| Net Margin |
-2%
|
| Country | US |
| Market Cap | 18.3B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 13.7B USD |
| Net Margin |
7%
|
| Country | DE |
| Market Cap | 12.4B EUR |
| Net Margin |
3%
|
| Country | AU |
| Market Cap | 13.4B AUD |
| Net Margin |
6%
|
Fulgent Genetics Inc
Glance View
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Fulgent Genetics Inc's most recent financial statements, the company has Net Margin of -59.4%.
You don't have any saved screeners yet
